BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 17541939)

  • 1. LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.
    Wu M; Huang C; Li X; Li X; Gan K; Chen Q; Tang Y; Tang K; Shen S; Li G
    J Cell Physiol; 2008 Jan; 214(1):65-74. PubMed ID: 17541939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
    Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
    J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP; Premkumar DR; Pollack IF
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of LRRC4 has the potential to decrease the growth rate and tumorigenesis of glioblastoma cell line U251.
    Wang JR; Li XL; Fan SQ; Tan C; Xiang JJ; Tang K; Wang R; Li GY
    Ai Zheng; 2003 Sep; 22(9):897-902. PubMed ID: 12969517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells.
    Parthymou A; Lampropoulou E; Mikelis C; Drosou G; Papadimitriou E
    Eur J Cell Biol; 2008 Jan; 87(1):17-29. PubMed ID: 17881084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
    Hong X; Jiang F; Kalkanis SN; Zhang ZG; Zhang X; Zheng X; Mikkelsen T; Jiang H; Chopp M
    J Exp Ther Oncol; 2007; 6(3):219-29. PubMed ID: 17552362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization.
    Wang R; Wang Z; Yang J; Liu X; Wang L; Guo X; Zeng F; Wu M; Li G
    J Cell Biochem; 2011 Dec; 112(12):3621-9. PubMed ID: 21809374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo.
    Ulbricht U; Eckerich C; Fillbrandt R; Westphal M; Lamszus K
    J Neurochem; 2006 Sep; 98(5):1497-506. PubMed ID: 16923162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
    Kimura Y; Sumiyoshi M; Baba K
    Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
    Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
    Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
    Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
    Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
    Thejass P; Kuttan G
    Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 13 cis-retinoic acid regulates cytokine production and inhibits angiogenesis by disrupting endothelial cell migration and tube formation.
    Guruvayoorappan C; Kuttan G
    J Exp Ther Oncol; 2008; 7(3):173-82. PubMed ID: 19066126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of integrin-linked kinase with a small interfering RNA inhibits endothelial cell migration, proliferation and tube formation in vitro.
    Guo L; Yu W; Li X; Zhao G; He P
    Ophthalmic Res; 2009; 42(4):213-20. PubMed ID: 19672130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis induced by VEGF under interstitial flow.
    Semino CE; Kamm RD; Lauffenburger DA
    Exp Cell Res; 2006 Feb; 312(3):289-98. PubMed ID: 16337626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation.
    Castañares C; Redondo-Horcajo M; Magán-Marchal N; ten Dijke P; Lamas S; Rodríguez-Pascual F
    J Cell Sci; 2007 Apr; 120(Pt 7):1256-66. PubMed ID: 17376964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets.
    Vizán P; Sánchez-Tena S; Alcarraz-Vizán G; Soler M; Messeguer R; Pujol MD; Lee WN; Cascante M
    Carcinogenesis; 2009 Jun; 30(6):946-52. PubMed ID: 19369582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.